S5 Ep13: New Year, New Hurdles: What's In Store For Biosimilars In 2023 Not So Different: A Podcast From The Center For Biosimilars podcast

Artwork

Fitness Audioboom Not So Different: a Podcast from The Center for Biosimilars United States

Player FM - Internet Radio Done Right

اضافه شده در seven سال پیش

محتوای ارائه شده توسط Audioboom and Not So Different: a Podcast from The Center for Biosimilars. تمام محتوای پادکست شامل قسمت‌ها، گرافیک‌ها و توضیحات پادکست مستقیماً توسط Audioboom and Not So Different: a Podcast from The Center for Biosimilars یا شریک پلتفرم پادکست آن‌ها آپلود و ارائه می‌شوند. اگر فکر می‌کنید شخصی بدون اجازه شما از اثر دارای حق نسخه‌برداری شما استفاده می‌کند، می‌توانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal

P

Peak Travel

Peak Travel podcast artwork

Peak Travel podcast artwork

1
Why Petra Needs Its People 28:39

15 روز پیش28:39

پخش در آینده

پخش در آینده

دوست داشته شد

28:39

For centuries, members of the B’doul Bedouin tribe lived in the caves around the ancient city of Petra, Jordan. Then, in the 1980s, the government forced the tribe to move in the name of preserving the geological site for tourists. But if the residents are forced to leave, and if their heritage has been permanently changed, then what exactly is being preserved? SHOW NOTES: Meet The Man Living in The Lost City Carved in Stone Jordan: Petra's tourism authority cracks down on Bedouin cave dwellers The tribes paying the brutal price of conservation “There is no future for Umm Sayhoun” Jordan’s Young Bedouins Are Documenting Their Traditions on TikTok Check out Sami's company Jordan Inspiration Tours Learn about your ad choices: dovetail.prx.org/ad-choices…

Not So Different: A Podcast from The Center for Biosimilars « »
S5 Ep13: New Year, New Hurdles: What's in Store for Biosimilars in 2023

۲ سال پیش 18:12

اشتراک گذاری

MP3•خانه قسمت

محتوای ارائه شده توسط Audioboom and Not So Different: a Podcast from The Center for Biosimilars. تمام محتوای پادکست شامل قسمت‌ها، گرافیک‌ها و توضیحات پادکست مستقیماً توسط Audioboom and Not So Different: a Podcast from The Center for Biosimilars یا شریک پلتفرم پادکست آن‌ها آپلود و ارائه می‌شوند. اگر فکر می‌کنید شخصی بدون اجازه شما از اثر دارای حق نسخه‌برداری شما استفاده می‌کند، می‌توانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal

To read more about adalimumab biosimilars, click here.
To read more about ophthalmology biosimilars, click here.
To learn more about the Inflation Reduction Act’s impact on biosimilars, click here.
To read more about the reauthorization of the Biosimilars User Fee Amendment, click here.
To learn more about interchangeability, click here.

… continue reading

155 قسمت

#Fitness #Audioboom #Not So Different: a Podcast from The Center for Biosimilars #United States

Artwork

S5 Ep13: New Year, New Hurdles: What's in Store for Biosimilars in 2023

Not So Different: A Podcast from The Center for Biosimilars

published ۲ سال پیش

اشتراک گذاری

MP3•خانه قسمت

محتوای ارائه شده توسط Audioboom and Not So Different: a Podcast from The Center for Biosimilars. تمام محتوای پادکست شامل قسمت‌ها، گرافیک‌ها و توضیحات پادکست مستقیماً توسط Audioboom and Not So Different: a Podcast from The Center for Biosimilars یا شریک پلتفرم پادکست آن‌ها آپلود و ارائه می‌شوند. اگر فکر می‌کنید شخصی بدون اجازه شما از اثر دارای حق نسخه‌برداری شما استفاده می‌کند، می‌توانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal

To read more about adalimumab biosimilars, click here.
To read more about ophthalmology biosimilars, click here.
To learn more about the Inflation Reduction Act’s impact on biosimilars, click here.
To read more about the reauthorization of the Biosimilars User Fee Amendment, click here.
To learn more about interchangeability, click here.

… continue reading

155 قسمت

#Fitness #Audioboom #Not So Different: a Podcast from The Center for Biosimilars #United States

همه قسمت ها

×

1
S7 Ep3: How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment 19:13

۵ weeks پیش19:13

پخش در آینده

پخش در آینده

دوست داشته شد

19:13

Show notes To learn more about the 10th anniversary of the first FDA biosimilar approval, click here . To learn more about how much biosimilars have saved so far, click here . To read more about Josh's views on the pharmaceutical landscape in 2025, click here .

1
S7 Ep2: Will the FTC Be More PBM-Friendly Under A Second Trump Administration? 28:55

۷ weeks پیش28:55

پخش در آینده

پخش در آینده

دوست داشته شد

28:55

Show notes To learn more about the FTC's most recent report on PBMs, click here . To learn more about the FTC's first report on PBMs, click here . To learn more about health care actions taken by the second Trump Administration during it's first month, click here . To learn more about the views of Mehmet Oz, MD (more commonly known as Dr. Oz) on price transparency ahead of his congressional confirmation hearings as President Trump's nominee for HHS Secretary, click here .…

1
S7 Ep1: Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals 14:17

۹ weeks پیش14:17

پخش در آینده

پخش در آینده

دوست داشته شد

14:17

Show notes 1. Jeremias S. A banner year for biosimilars: The 19 FDA approvals from 2024. The Center for Biosimilars. January 21, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/a-banner-year-for-biosimilars-the-18-fda-approvals-from-2024 2. Jeremias S. FDA approves Celltrion's Avtozma as third tocilizumab biosimilar. The Center for Biosimilars. January 31, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/fda-approves-celltrion-s-avtozma-as-third-tocilizumab-biosimilar 3. Jeremias S. Senators introduce bipartisan legislation to protect skinny labeling. The Center for Biosimilars. January 2, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/senators-introduce-bipartisan-legislation-to-protect-skinny-labeling 4. Jeremias S. FTC releases second report on PBMs meddling in generic drug markets. The Center for Biosimilars. January 19, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/ftc-releases-second-report-on-pbms-meddling-in-generic-drug-markets 5. Santoro C. Earlier patent litigation could accelerate US biosimilar market entry. The Center for Biosimilars. January 9, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/earlier-patent-litigation-could-accelerate-us-biosimilar-market-entry 6. Jeremias S. Welcome Wezlana: the first Stelara biosimilar to launch in the US. The Center for Biosimilars. January 31, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/welcome-wezlana-the-first-stelara-biosimilar-to-launch-in-the-us 7. Jeremias S, Chambers JD. The banking of biosimilars: insights from a leading health economist. The Center for Biosimilars. February 4, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/the-banking-of-biosimilars-insights-from-a-leading-health-economist 8. Jeremias S. The biosimilar void: 90% of biologics coming off patent will lack biosimilars. The Center for Biosimilars. February 5, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/the-biosimilar-void-90-of-biologics-coming-off-patent-will-lack-biosimilars 9. Jeremias S. Biosimilars drive cost savings and achieve 53% market share across treatment areas. The Center for Biosimilars. January 16, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/biosimilars-drive-cost-savings-and-achieve-53-market-share-across-treatment-areas…

1
S6 Ep41: The Top 5 Most-Listened to Podcasts of 2024 5:15

15 weeks پیش5:15

پخش در آینده

پخش در آینده

دوست داشته شد

5:15

Here are the top 5 episodes of Not So Different from 2024. Number 5: Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved Number 4: Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars Number 3: Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report Number 2: Biosimilars in America: Overcoming Barriers and Maximizing Impact Number 1: Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024…

1
S6 Ep40: Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition 5:47

19 weeks پیش5:47

پخش در آینده

پخش در آینده

دوست داشته شد

5:47

Show Notes 1. Jeremias S. Skyrizi overtakes Humira: “product hopping” leaves biosimilar market in limbo. The Center for Biosimilars. November 7, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/skyrizi-overtakes-humira-product-hopping-leaves-biosimilar-market-in-limbo 2. Jeremias S. Celltrion sets sights on 2030 with expanded biosimilar portfolio, market reach. The Center for Biosimilars. November 6, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/celltrion-sets-sights-on-2030-with-expanded-biosimilar-portfolio-market-reach 3. Ferreri D. Making the cost of IBD care sustainable. The Center for Biosimilars. November 2, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/making-the-cost-of-ibd-care-sustainable 4. Ferreri D. Achieving PFS in advanced gastric cancer with HLX02 biosimilar, chemotherapy. The Center for Biosimilars. November 23, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/achieving-pfs-in-advanced-gastric-cancer-with-hlx02-biosimilar-chemotherapy 5. Ferreri D. Subcutaneous infliximab CT-P13 superior to placebo as maintenance therapy for IBD . The Center for Biosimilars. November 16, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/subcutaneous-infliximab-ct-p13-superior-to-placebo-as-maintenance-therapy-for-ibd 6. Ferreri D. Challenges, obstacles, and future directions for anti-TNF biosimilars in IBD. The Center for Biosimilars.November 9, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/challenges-obstacles-and-future-directions-for-anti-tnf-biosimilars-in-ibd 7. Jeremias S. Breaking down biosimilar barriers: the patent system.The Center for Biosimilars. November 11, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/breaking-down-biosimilar-barriers-the-patent-system 8. Jeremias S. Breaking down biosimilar barriers: payer and PBM policies. The Center for Biosimilars. November 13, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/breaking-down-biosimilar-barriers-payer-and-pbm-policies 9. Poore D. Breaking down biosimilar barriers: interchangeability. The Center for Biosimilars. November 14, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/breaking-down-biosimilar-barriers-interchangeability 10. The Center for Biosimilars Staff. Webinar: streamlining the regulatory process to advance access to biosimilars. The Center for Biosimilars. November 21, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/webinar-streamlining-the-regulatory-process-to-advance-access-to-biosimilars 11. Jeremias S. Can global policies to boost biosimilar adoption work in the US? The Center for Biosimilars. November 17, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/can-global-policies-to-boost-biosimilar-adoption-work-in-the-us -…

1
S6 Ep39: Can Global Policies to Boost Biosimilar Adoption Work in the US? 21:49

21 weeks پیش21:49

پخش در آینده

پخش در آینده

دوست داشته شد

21:49

Show notes To learn more about GBW, click here . To check out our coverage of the recent GRx+Biosims conference Craig mentioned, click here . To learn more about product hopping, click here . To read part 1 of our GBW series, click here . To read part 2 of our GBW series, click here . To read part 3 of our GBW series, click here . To hear another episode featuring more of Craig's thoughts on the Biden's administration's impact on the biosimilar industry, click here .…

1
S6 Ep38: Biosimilars Development Roundup for October 2024—Podcast Edition 5:20

23 weeks پیش5:20

پخش در آینده

پخش در آینده

دوست داشته شد

5:20

Show notes 1. Jeremias S. Strengthening the supply chain: key insights from FDA commissioner Dr Robert Califf. The Center for Biosimilars®. October 25, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/strengthening-the-supply-chain-key-insights-from-fda-commissioner-robert-califf 2. Jeremias S. FDA and industry experts unpack biosimilar device requirements. The Center for Biosimilars. October 23, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/fda-and-industry-experts-unpack-biosimilar-device-requirements 3. Jeremias S. Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims. The Center for Biosimilars. October 23, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/calling-for-unified-biosimilar-standards-stronger-education-at-grx-biosims 4. Jeremias S. Unifying standards: the need for streamlined biosimilar development. The Center for Biosimilars. October 22, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/unifying-standards-the-need-for-streamlined-biosimilar-development 5. Jeremias S. Enhancing Adoption of Infused Biosimilars for a Sustainable Future. The Center for Biosimilars. October 30, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/enhancing-adoption-of-infused-biosimilars-for-a-sustainable-future 6. Jeremias S. IQVIA webinar: enhancing regulatory strategies for biosimilars and generics. The Center for Biosimilars. October 14, 2024. Accessed November 1, 2024. https://www.centerforbiosimilars.com/view/iqvia-webinar-enhancing-regulatory-strategies-for-biosimilars-and-generics…

1
S6 Ep37: Biosimilars Policy Roundup for September 2024—Podcast Edition 7:52

27 weeks پیش7:52

پخش در آینده

پخش در آینده

دوست داشته شد

7:52

Show notes 1. FDA Approves Pavblu for Retinal Conditions 2. AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1 3. Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys 4. The Future of Biosimilar Gene Therapies: Key Issues and Potential 5. IRA Reimbursement Impact on Biosimilars Minimal Despite Rising Market Share 6. The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings 7. France Study Finds High Patient Satisfaction With Adalimumab Biosimilar Treatment for IBD…

1
S6 Ep36: Biosimilars Business Roundup for August 2024—Podcast Edition 5:22

32 weeks پیش5:22

پخش در آینده

پخش در آینده

دوست داشته شد

5:22

Show notes 1. Sandoz Reports 29% Growth in Biosimilar Revenues for First Half of 2024 2. Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 2024 3. Formycon Reports €26.9 Million Revenue for First Half 2024, Driven by Biosimilars 4. CMS Announces New Drug Prices Under the IRA, Including for Stelara and Enbrel 5. FDA Approves Biosimilar Enzeevu for Eye Conditions 6. Manitoba Adopts Biosimilar Switching Policy 7. Eye on Pharma: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results 8. Vizient Report Projects Price Inflation for Originators With Biosimilars in the Pipeline…

1
S6 Ep35: Biosimilars Policy Roundup for July 2024—Podcast Edition 5:12

36 weeks پیش5:12

پخش در آینده

پخش در آینده

دوست داشته شد

5:12

Show notes 1. FDA Approves Samsung Bioepis’ Pyzchiva, a Biosimilar to Stelara 2. Ahzantive Receives FDA Approval as New Eylea Biosimilar 3. FDA Approves Epysqli as Second Soliris Biosimilar 4. BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed 5. Biosimilars and Employers: Strategies for Success 6. Learning the Lingo of Biologics and Biosimilars Is Critical 7. Singapore Experience Shows Benefits of Value-Driven Strategies in Generating Biosimilar Savings 8. Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch…

1
S6 Ep34: Biosimilars in America: Overcoming Barriers and Maximizing Impact 27:23

38 weeks پیش27:23

پخش در آینده

پخش در آینده

دوست داشته شد

27:23

Show notes To learn more about Cencora and their efforts, click here . To learn more about the Inflation Reduction Act's impact on biosimilars, click here .

1
S6 Ep33: Biosimilars Oncology Roundup for June 2024—Podcast Edition 6:14

40 weeks پیش6:14

پخش در آینده

پخش در آینده

دوست داشته شد

6:14

Show notes 1. Biosimilars Check-In: Application Acceptances, European Approvals, New Partnerships 2. Overcoming Economic, Noneconomic Barriers to Biosimilar Adoption in Oncology 3. EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions 4. New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers 5. ASCO Posters Reflect on Reimbursement Trends, Combination Therapies Involving Biosimilars 6. ASCO 2024 Posters Showcase Positive Data on Denosumab, Pegfilgrastim Biosimilars 7. Authors Spotlight Long-Term Solutions to Ensure Biosimilar Market Sustainability 8. Part 2: Unlocking the Potential of Biosimilars to Improve Health Equity…

1
S6 Ep32: Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved 27:45

43 weeks پیش27:45

پخش در آینده

پخش در آینده

دوست داشته شد

27:45

To learn more about the approval of denosumab-bddz, click here . To watch Curtis and Edgerton speak on the approval of denosumab-bddz and osteoporosis treatment, click here . To learn more about the ROSALIA study (NCT05405725), click here . Extra content: To read more about the Biosimilars Council position paper on how to improve biosimilar development, click here .…

1
S6 Ep31: Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition 5:16

45 weeks پیش5:16

پخش در آینده

پخش در آینده

دوست داشته شد

5:16

Show notes FDA Approves High-Concentration Cyltezo Eye on Pharma: Simlandi US Launch; Ranibizumab Partnership; Expanded Access for Adalimumab Biosimilars DDW 2024 Posters Evaluate Safety, Efficacy, Impact of BMI on Zymfentra Use Posters Demonstrate Switching Safety Between Originator, Biosimilar Infliximab in IBD New Evidence Confirms Safe Biosimilar-to-Biosimilar Switching Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment…

1
S6 Ep30: Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report 14:53

47 weeks پیش14:53

پخش در آینده

پخش در آینده

دوست داشته شد

14:53

Show notes To read our coverage of the Cardinal Health report, click here . To read the full report, click here . To check out The Center for Biosimilars coverage of Festival of Biologics USA, click here .

به Player FM خوش آمدید!

Player FM در سراسر وب را برای یافتن پادکست های با کیفیت اسکن می کند تا همین الان لذت ببرید. این بهترین برنامه ی پادکست است که در اندروید، آیفون و وب کار می کند. ثبت نام کنید تا اشتراک های شما در بین دستگاه های مختلف همگام سازی شود.

به بیش از 500 موضوع گوش کنید

در حین کاوش به این نمایش گوش دهید